Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rEV131 for Prevention of Allergic Rhinitis Symptoms
NCT00247520Phase 2Unknown
- Sponsor
- Nanoco
- Start
- May 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rEV131 in allergic rhinitis (AR) (5 arms), sponsored by Nanoco. Primary endpoint: Total Nasal Symptom Score at 15 months. Status: unknown.
02
Drugs
rEV131
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT00247520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00247520.